Micromedic Technologies Ltd. – a Unique Cluster of Cancer Diagnostic Solutions
|
Company Profile Micromedic Technologies Ltd. is a public company traded on the Tel Aviv Stock Exchange (MCTC), focusing on the development and commercialization of cancer diagnostics products.Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence,Micromedic identifies projects that fill unmet needs in various cancer related... Read moreMicromedic Technologies Ltd. is a public company traded on the Tel Aviv Stock Exchange (MCTC), focusing on the development and commercialization of cancer diagnostics products.
Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence,
Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products.
Micromedic operates through strategic collaborations and in-licensing from leading scientific institutes worldwide as well as in-house based research.
As of December 2011 the company's larger share holder, BioLight Life Sciences Investments (TASE: BOLT, OTCQX: BLGTY), realizes its clusters approach by forming the “Cancer Diagnostic Cluster”. | |
|
Executives
Stevan Eitan, CEO
| |
Products
Micromedic Technologies Ltd. specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. Our portfolio includes state-of-the-art technologies involving gene expression, biomarker and histochemical assays for early cancer detection and personalized medicine.
Micromedic offers proprietary diagnostic solutions for multiple cancer diagnostic applications, providing practical answers to real unmet needs.
Diagnostics
